A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors

The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.

Trial Details

NCT ID
NCT07107230
Phase
PHASE1
Sponsor
Janssen Research & Development, LLC
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • JNJ-95437446
Locations (sample)
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Fairfax, Virginia, United States|38.84622,-77.30637
  • Seoul, South Korea|37.566,126.9784
  • Seoul, South Korea|37.566,126.9784
  • Barcelona, Spain|41.38879,2.15899

Key Eligibility Criteria

  • Participants must have been previously diagnosed with histologically confirmed unresectable, locally advanced, or metastatic non-small cell lung ca…
  • Participants with non-small cell lung cancer (NSCLC) adenocarcinoma and colorectal cancer (CRC) must have local molecular testing to determine epid…
  • Have measurable or evaluable disease:
  • Part 1: Either measurable or evaluable disease; Part 2: At least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) vers…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →